A new device to relieve pain without surgery or opioids
Official title: Opioid-Sparing Non-Surgical, Bioresorbable Nerve Stimulator for Pain Relief
Funded at Vanish Therapeutics INC. · NIH-10932412 · Data updated 2026-11-12
This study is testing a new type of nerve stimulator that can help relieve chronic pain without surgery or opioids, and it safely dissolves in your body after about two months.
Quick facts
| Grant type | NIH-funded research |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Vanish Therapeutics INC. NIH-funded |
| Lab location | 1 site (Mars, United States) |
| Project start | September 20, 2023 |
| Project end | August 31, 2025 |
| Funding year | 2024 |
| Award (this year) | $346,517 |
| NIH project number | 5R41NS132625-02 |
| Project ID | NIH-10932412 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research are individuals experiencing chronic pain who are seeking non-opioid treatment options.
✕Less likely to help
Patients with acute pain conditions or those who do not respond to nerve stimulation may not benefit from this research.
What this research studies
This research investigates a novel bioresorbable nerve stimulator designed to alleviate chronic pain without the need for surgical implantation or opioid medications. The device is placed near a peripheral nerve and uses electrical signals to modulate pain perception. Unlike traditional nerve stimulators, which are made of permanent materials and require surgery for removal, this device safely degrades in the body after providing pain relief for up to 60 days. This approach aims to reduce complications and improve patient outcomes in pain management.
Why it matters
Potential benefit: If successful, this research could provide a safer and more effective pain relief option for patients suffering from chronic pain.
How similar studies have gone: While nerve stimulation has been used in various forms, this bioresorbable approach is novel and has not been extensively tested in clinical settings.
Where this research is happening
-
Vanish Therapeutics INC.
Mars, United States Active
Researchers
- Principal investigator: Cui, Xinyan Tracy — Vanish Therapeutics INC.
- Study coordinator: Cui, Xinyan Tracy
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.